Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic-Guided Neoadjuvant Chemotherapy in Early Breast Cancer
NCT00636441Phase 2Terminated
- Sponsor
- Duke University
- Start
- Apr 2008
- Primary completion
- Apr 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, cyclophosphamide, docetaxel in breast cancer, sponsored by Duke University. Started Apr 2008; status: terminated.
02
Drugs
doxorubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00636441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636441.